Browse > Article

The Effect of Depression and Anxiety Symptoms on the Results of Combined Dexamethasone/Corticotropin Releasing Hormone Test in Patients with Schizophrenia  

Han, Byung-Jin (Comfort-mind Psychiatric Clinic)
Lee, Sang-Ick (Department of Psychiatry, Chungbuk National University School of Medicine)
Shin, Chul-Jin (Department of Psychiatry, Chungbuk National University School of Medicine)
Son, Jung-Woo (Department of Psychiatry, Chungbuk National University School of Medicine)
Publication Information
Korean Journal of Biological Psychiatry / v.17, no.2, 2010 , pp. 86-93 More about this Journal
Abstract
Objectives : The aim of this research is to determine the effects of depression and anxiety symptoms of schizophrenic psychopathology on the HPA axis. Methods : Twenty patients with schizophrenia were included and divided into the medication non-exposed group(n = 10) and the medication exposed group(n = 10). Evaluated scales were the Positive and Negative Syndrome Scale(PANSS), Scale for the Assessment of Negative Symptoms(SANS), Scale for the Assessment of Positive Symptoms(SAPS), Hamilton Depression Inventory(HAM-D) and Hamilton Anxiety Inventory (HAM-A), and then the combined Dexamethasone/Corticotropin Releasing Hormone(DEX/CRH) test was conducted to determine the basal level, the peak level and the area under the curve(AUC) of cortisol and adrenocorticotropic hormone(ACTH). Results : When the correlations between each psychopathology and cortisol level or ACTH AUC value were analyzed, HAM-D showed a negative correlation, whereas HAM-A showed a positive correlation. Also, the non-depression group(HAM-D ${\leq}$ 18) showed higher cortisol and ACTH concentrations than the depression group(HAM-D > 18), and the anxiety group(HAM-A ${\geq}$ 14) showed significantly higher concentrations than the non-anxiety group(HAM-D < 14)(p < 0.05). Also, as for the comparison between the medication non-exposed group and the medication exposed group, the non-exposed group showed significantly higher cortisol and ACTH concentration than exposed group(p < 0.05). Conclusion : This study suggest that anxiety symptoms rather than depression symptoms are related to the increased activity of the HPA axis of schizophrenics.
Keywords
Schizophrenia; HPA axis; Anxiety; Depression;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.   DOI   ScienceOn
2 Rubin R, Dinan TG , Scott LV. The neuroendocrinology of affective disorders. In: Pfaff D, Arnold AP, Etgen AM, Fahrbach SE, Moss RL, Rubin RT, editors. Hormone, Brain and Behaviour. New York: Academic Press; 2001. p.230-245.
3 Yeragani VK. The incidence of abnormal dexamethasone suppression test in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry 1990;35:128-132.   DOI
4 Gil-Ad I, Dickerman Z, Amdursky S, Laron Z. Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compaired to control subjects. Psychopharmacology(Berl)1986;88:496-499.
5 Kaneko M, Yokoyama F, Hoshino Y, Takahagi K, Murata S, Watanabe M, et al. Hypothalamic-pituitaryadrenal function in chronic schizophrenia: association with clinical features. Neuropsychobiology 1992;25:1-7.   DOI
6 Ismail K, Murray RM, Wheeler MJ, O'keane V. The dexamethasone suppression test in schizophrenia. Psychol Med 1998;28:311-317.   DOI   ScienceOn
7 Coppen A, Abou-Salch M, Millin P, Metcalfe M, Harwood J, Bailey J. Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry 1983;142:498-504.   DOI   ScienceOn
8 Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador- Woodruff JH, Goldman R, et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 1991;29:953-964.   DOI   ScienceOn
9 Roy A, Pickar D, Doran A, Wolkowitz O, Gallucci W, Chrousos G, et al. The corticotropin-releasing hormone stimulation test in chronic schizophrenia. Am J Psychiatry 1986;143:1393-1397.   DOI
10 Holsboer-Taschsler E, Buol C, Wiedemann K, Holsboer F. Dexamethasone suppression test in severe schizophrenic illness: effect of plasma dexamethasone and caffeine levels. Acta Psychiatry Scand 1987;75:608-613.   DOI   ScienceOn
11 Baumgartner A, Graf KJ, Kurten I. Serial dexamethasone suppression test in psychiatric illness: Part I. A study in schizophrenia and mania. Psychiatry Res 1986; 18:25-43.   DOI   ScienceOn
12 Heuser I, Yassouridis A, Holsboer F. The dexamethasone/ CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.   DOI   ScienceOn
13 Halbreich U, Zumoff B, Kream J, Fukushima DK. The mean 1300-1600h plasma cortisol concentration as a diagnostic test for hypercortisolism. J Clin Endocri-nol Metab 1982;54:1262 -1264.   DOI
14 Andreasen NC, Flaum M, Swayze VW 2nd, Tyrrell G , Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 1990;47: 615-621.   DOI   ScienceOn
15 Kraus RP, Hux M, Grof P. Psychotropic drug withdrawl and the dexamethasone suppression test. Am J Psychiatry 1987;144:82-85.   DOI
16 Kay SR, Fiszbein A, Opler LA. Positive and negative syndrome scale(PANSS)for schizophrenia. Schizophr Bull 1987;13:261-276.   DOI   ScienceOn
17 Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
18 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.   DOI
19 Lammers CH, Garcia-Borreguero D, Schimider J, Gotthardt U, Dettling M, Holsboer F, et al. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry 1995;38:803-807.   DOI   ScienceOn
20 Kim KS, Sung YS, Chae JH, Bahk WM, Lee CT, Jun TY. Changes in serum cortisol levels and clinical symptoms after the administration of risperidone in schizophrenic patients. J Korean Neuropsychiatr Assoc 2003; 39:381-389.
21 Pivac N, Muck-Seler D, Jakovljevie M. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 1997;36:19-21.   DOI   ScienceOn
22 Jakovljevic M, Muck-Seler D, Pivac N, Crncevic Z. Platelet 5-HT and plasma cortisol concentration after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology 1998;37:142-145.   DOI   ScienceOn
23 Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 1999;45:1433-1439.   DOI   ScienceOn
24 Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin- releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995;38:797-802.   DOI   ScienceOn
25 Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Brain Res Rev 1993;18:1-32.
26 Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitary- adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:935-938.   DOI   ScienceOn
27 Dewan MJ, Pandurangi AK, Boucher ML, Levy BF, Major LF. Abnormal dexamethasone suppression test results in chronic schizophrenic patients. Am J Psychiatry 1982;139:1501-1503.   DOI
28 Sharma RP, Pandey GN, Janicak PG, Peterson J, Comaty JE, Davis JM. The effect of diagnosis and age on the DST: a metaanalytic approach. Biol Psychiatry 1988; 24:555-568.   DOI   ScienceOn
29 Addington D, Addington J. Depression dexamethasone nonsuppression and negative symptoms in schizophrenia. Can J Psychiatry 1990;35:430-433.   DOI